JAK2 and myeloproliferative neoplasm: Clinical evidence for the relevance of this domain was obtained in 2005, when an acquired point mutation in the JH2 domain of JAK2 (Val 617 to Phe substitution, V617F) was identified in myeloproliferative neoplasm (MPN) patients [6], [7], [8], [9].